Apogee Therapeutics, Inc. Common Stock (APGE)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $10.22B
Last updated: Sep 04, 2026 at 5:00 PM ET
Apogee Therapeutics, Inc. Common Stock (APGE) Financials: Revenue, Profit and Cash Flow
Apogee Therapeutics, Inc. Common Stock reported revenue of $0 for the fiscal year ended Dec 31, 2025. That year, net income was -$255.84M, operating cash flow was -$227.45M and free cash flow was -$232.60M. The quarter ended Jun 30, 2026 had revenue of $0 and net income of -$85.85M.
Revenue and Margins
The company reported no revenue in the fiscal year ended Dec 2025, with an operating loss of $285.60M.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $0 | N/A | N/A | N/A | N/A |
| Dec 2024 | $0 | N/A | N/A | N/A | N/A |
| Dec 2023 | $0 | N/A | N/A | N/A | N/A |
| Dec 2022 | $0 | N/A | N/A | N/A | N/A |
Income Statement
In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Jun 2026, the net loss widened from the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Research and development | $214.71M | $167.87M | $68.42M | $27.79M |
| Operating income | -$285.60M | -$216.87M | -$93.00M | -$30.73M |
| Net income | -$255.84M | -$182.15M | -$83.98M | -$39.78M |
Quarterly
| Line item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $130.00K | $0 | $0 | $0 | $0 | $0 |
| Gross profit | $0 | $0 | $400.00K | $0 | $0 | $0 | $65.00K | $0 | $0 | $0 | N/A | $0 |
| Operating income | -$96.00M | -$82.77M | -$78.06M | -$71.28M | -$73.17M | -$63.10M | -$75.88M | -$58.69M | -$44.12M | -$38.18M | -$37.16M | -$24.30M |
| Net income | -$85.85M | -$74.11M | -$69.39M | -$65.02M | -$66.10M | -$55.34M | -$67.22M | -$49.02M | -$33.82M | -$32.09M | -$31.73M | -$20.84M |
Balance Sheet
As of Dec 2025, cash and equivalents exceeded short-term debt of $3.50M by $128.04M.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Total assets | $937.13M | $753.95M | $401.40M | $152.06M |
| Current assets | $741.36M | $529.71M | $398.41M | $152.06M |
| Cash and equivalents | $131.55M | $141.79M | $118.32M | $151.89M |
| Total liabilities | $33.25M | $37.16M | $21.49M | $9.98M |
| Short-term debt | $3.50M | $3.23M | $1.10M | N/A |
| Shareholder equity | $903.88M | $716.79M | $379.91M | -$35.39M |
Quarterly
| Line item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $1.34B | $1.29B | $937.13M | $626.16M | $657.77M | $714.16M | $753.95M | $776.29M | $800.66M | $823.66M | $401.40M | $426.42M |
| Total liabilities | $141.21M | $37.86M | $33.25M | $39.82M | $38.37M | $40.80M | $37.16M | $41.88M | $27.02M | $22.18M | $21.49M | $17.18M |
| Cash and equivalents | $105.57M | $451.80M | $131.55M | $107.91M | $124.19M | $106.92M | $141.79M | $118.78M | $307.30M | $485.46M | $118.32M | $188.27M |
| Shareholder equity | $1.19B | $1.26B | $903.88M | $586.34M | $619.40M | $673.36M | $716.79M | $734.40M | $773.64M | $801.48M | $379.91M | $409.24M |
Cash Flow
Operating cash flow was negative in the fiscal year ended Dec 2025.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Operating cash flow | -$227.45M | -$171.17M | -$74.76M | -$16.43M |
| Capital expenditures | $5.15M | $1.15M | $167.00K | $0 |
| Free cash flow | -$232.60M | -$172.33M | -$74.93M | -$16.43M |
| Investing cash flow | -$179.57M | -$300.46M | -$273.91M | N/A |
| Financing cash flow | $396.49M | $495.11M | $315.39M | $168.32M |
Quarterly
| Line item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$71.38M | -$55.57M | -$62.69M | -$54.26M | -$62.03M | -$48.48M | -$67.71M | -$42.52M | -$29.30M | -$31.64M | -$29.75M | -$19.88M |
| Capital expenditures | $6.00K | $0 | $62.00K | $0 | $768.00K | $4.32M | $1.00K | $751.00K | $51.00K | $351.00K | $167.00K | $0 |
| Free cash flow | -$71.39M | -$55.57M | -$62.75M | -$54.26M | -$62.80M | -$52.79M | -$67.72M | -$43.27M | -$29.35M | -$31.99M | -$29.92M | -$19.88M |
Frequently Asked Questions About APGE
What is Apogee Therapeutics, Inc. Common Stock's annual revenue?
Apogee Therapeutics, Inc. Common Stock reported revenue of $0 for the fiscal year ended Dec 31, 2025.
Is Apogee Therapeutics, Inc. Common Stock profitable?
No. Apogee Therapeutics, Inc. Common Stock reported net income of -$255.84M for the fiscal year ended Dec 31, 2025.
How much free cash flow does APGE generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of -$227.45M minus capital expenditures of $5.15M produced free cash flow of -$232.60M.
How much debt does Apogee Therapeutics, Inc. Common Stock have?
The balance sheet dated Dec 31, 2025 reported short-term debt of $3.50M and cash and equivalents of $131.55M.
APGE pages: Overview, Financials